Surmodics (SRDX)
(Delayed Data from NSDQ)
$34.55 USD
+1.22 (3.66%)
Updated May 2, 2024 04:00 PM ET
After-Market: $34.50 -0.05 (-0.14%) 7:46 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
SurModics (SRDX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$58.50 | $70.00 | $47.00 | 75.52% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for SurModics comes to $58.50. The forecasts range from a low of $47.00 to a high of $70.00. The average price target represents an increase of 75.52% from the last closing price of $33.33.
Analyst Price Targets (2 )
Broker Rating
SurModics currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by two brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on two recommendations.
Of the two recommendations deriving the current ABR, one is Strong Buy and one is Buy. Strong Buy and Buy each account for 50% of all recommendations. A month ago, Strong Buy made up 50%, while Buy represented 50%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/10/2024 | Needham & Company | Michael Matson | Moderate Buy | Moderate Buy |
11/9/2023 | Barrington Research | Michael J Petusky | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 2 |
Average Target Price | $58.50 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 151 of 252 |
Current Quarter EPS Est: | -0.29 |